Skip to main content

Antibody-Mediated Rejection

4
Pipeline Programs
5
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
6100%
+ 4 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
3 programs
1
2
C1-esterase inhibitorPhase 3
ClazakizumabPhase 3Monoclonal Antibody
Clazakizumab / ClazakizumabPhase 2Monoclonal Antibody
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ALXN2030Phase 21 trial
Active Trials
NCT06744647Recruiting45Est. Nov 2028
CSL Behring
CSL BehringIL - Bradley
3 programs
Clazakizumab / ClazakizumabPHASE_2Monoclonal Antibody1 trial
C1-esterase inhibitorPHASE_31 trial
ClazakizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT03444103Completed20Est. Jun 2020
NCT03221842Terminated63Est. Jan 2021
NCT03744910Terminated194Est. Apr 2024
Biogen
BiogenCAMBRIDGE, MA
2 programs
FelzartamabPHASE_3Monoclonal Antibody1 trial
FelzartamabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT06685757Recruiting120Est. Jun 2027
NCT07444489Enrolling By Invitation120Est. May 2031
argenx
argenxBelgium - Zwijnaarde
1 program
Efgartigimod PH20 SC - prefilled syringePHASE_21 trial
Active Trials
NCT06503731Recruiting30Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BiogenFelzartamab
BiogenFelzartamab
CSL BehringClazakizumab
CSL BehringC1-esterase inhibitor
AstraZenecaALXN2030
argenxEfgartigimod PH20 SC - prefilled syringe
CSL BehringClazakizumab / Clazakizumab

Clinical Trials (7)

Total enrollment: 592 patients across 7 trials

NCT07444489BiogenFelzartamab

A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Start: Apr 2026Est. completion: May 2031120 patients
Phase 3Enrolling By Invitation
NCT06685757BiogenFelzartamab

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

Start: Dec 2024Est. completion: Jun 2027120 patients
Phase 3Recruiting
NCT03744910CSL BehringClazakizumab

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients

Start: Oct 2019Est. completion: Apr 2024194 patients
Phase 3Terminated
NCT03221842CSL BehringC1-esterase inhibitor

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Start: Nov 2017Est. completion: Jan 202163 patients
Phase 3Terminated
NCT06744647AstraZenecaALXN2030

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

Start: Mar 2025Est. completion: Nov 202845 patients
Phase 2Recruiting
NCT06503731argenxEfgartigimod PH20 SC - prefilled syringe

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

Start: Aug 2024Est. completion: Sep 202730 patients
Phase 2Recruiting
NCT03444103CSL BehringClazakizumab / Clazakizumab

A Pilot Trial of Clazakizumab in Late ABMR

Start: Jan 2018Est. completion: Jun 202020 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
3 actively recruiting trials targeting 592 patients
Monoclonal Antibody is the dominant modality (100% of programs)
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.